Distinct relations among plasma concentrations required for different pharmacological effects in oxycodone, morphine, and fentanyl

Journal of Pain and Palliative Care Pharmacotherapy

Volumn 25, Issue 4, 2011, Pages 318-334

  Nakamura, Atsushi ^a,b   Hasegawa, Minoru ^a   Ito, Hisanori ^a   Minami, Kazuhisa ^a   Koike, Katsumi ^a   Habu Tomita, Naoko ^a   Nanba, Kenkichi ^a   Hamaguchi, Kayo ^a   Noshi, Eriko ^a   Hashimoto, Hiroshi ^a   Nishino, Ikuko ^a   Okabayashi, Yoshito ^a   Koyabu, Kiyotaka ^a   Kihara, Tsuyoshi ^a   Iwamoto, Yuka ^a   Inoue, Yuji ^a   Narita, Minoru ^b   Suzuki, Tsutomu ^b   Kato, Akira ^a  

^a SHIONOGI AND CO LTD   (Japan)

^b HOSHI UNIVERSITY   (Japan)

Author keywords

Adverse effects; Antinociceptive effect; Fentanyl; Morphine; Oxycodone

Indexed keywords

FENTANYL; FENTANYL CITRATE; MORPHINE; OXYCODONE;

ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR DISORDER; CONSTIPATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG MECHANISM; MALE; NOCICEPTION; NONHUMAN; RAT; RESPIRATION DEPRESSION;

ANALGESICS; ANALGESICS, OPIOID; ANIMALS; BRAIN; CONSTIPATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FENTANYL; MALE; MODELS, ANIMAL; MORPHINE; OXYCODONE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 82455163838     PISSN: 15360288     EISSN: 15360539     Source Type: Journal    
DOI: 10.3109/15360288.2011.620689     Document Type: Article

References (24)

1. Twycross RG, Lack SA. Control of Alimentary Symptoms in Far Advanced Cancer. London: Churchill Livingstone, London; 1986:166-207.
2. Bruera E, Watanabe S. Psychostimulants as adjuvant analgesics. J Pain Symptom Manage. 1994;9:412-415. (Pubitemid 24278159)
3. O'Mahony S, Coyle N, Payne R. Current management of opioid-related side effects. Oncology (Williston Park). 2001;15:61-73, 77-78, 80-82.
4. McNicol E, Horowicz-Mehler N, Fisk RA, Bennett K, Gialeli-Goudas M, Chew PW, Lau J, Carr D, American Pain Society. Management of opioid side effects in cancer-related and chronic noncancer pain: a systematic review. J Pain. 2003;4:231-256. (Pubitemid 36807905)
5. Hartung DM, Middleton L, Haxby DG, Koder M, Ketchum KL, Chou R. Rates of adverse events of long-acting opioids in a state Medicaid program. Ann Pharmacother. 2007;41:921-928. (Pubitemid 46917617)
6. Ordonez Gallego A, Gonzalez Baron M, Espinosa Arranz E. Oxycodone: a pharmacological and clinical review. Clin Transl Oncol. 2007;9:298-307.
7. Narabayashi M, Saijo Y, Takenoshita S, Chida M, Shimoyama N, Miura T, Tani K, Nishimura K, Onozawa Y, Hosokawa T, Kamoto T, Tsushima T, Advisory Committee for Oxycodone Study. Opioid rotation from oral morphine to oral oxycodone in cancer patients with intolerable adverse effects: an open-label trial. Jpn J Clin Oncol. 2008;38:296-304. (Pubitemid 351583994)
8. Megens AA, Artois K, Vermeire J, Meert T, Awouters FH. Comparison of the analgesic and intestinal effects of fentanyl and morphine in rats. J Pain Symptom Manage. 1998;15:253-257.
9. Lotsch J. Pharmacokinetic-pharmacodynamic modeling of opi-oids. J Pain Symptom Manage. 2005;29:S90-S103.
10. Mucci-LoRusso P, Berman BS, Silberstein PT, Citron ML, Bressler L, Weinstein SM, Kaiko RF, Buckley BJ, Reder RF. Controlled-release oxycodone compared with controlled-release morphine in the treatment of cancer pain: a randomized, double-blind, parallel-group study. Eur J Pain. 1998;2:239-249. (Pubitemid 28474354)
11. Staahl C, Upton R, Foster DJ, Christrup LL, Kristensen K, Hansen SH, Arendt-Nielsen L, Drewes AM. Pharmacokinetic-pharmacodynamic modeling of morphine and oxycodone concentrations and analgesic effect in a multimodal experimental pain model. J Clin Pharmacol. 2008;48:619-631. (Pubitemid 351503514)
12. Narita M, Imai S, Itou Y, Yajima Y, Suzuki T. Possible involvement of mu1-opioid receptors in the fentanyl-or morphine-induced anti-nociceptive effect at supraspinal and spinal sites. Life Sci. 2002;70:2341-2354. (Pubitemid 34261045)
13. Narita M, Nakamura A, Ozaki M, Imai S, Miyoshi K, Suzuki M, Suzuki T. Comparative pharmacological Profles of morphine and oxycodone under a neuropathic pain-like state in mice: evidence for less sensitivity to morphine. Neuropsychopharmacology. 2008;33:1097-1112. (Pubitemid 351367533)
14. Lemberg KK, Kontinen VK, Siiskonen AO, Viljakka KM, Yli-Kauhaluoma JT, Korpi ER, Kalso EA. Anti-nociceptive effect by spinal and systemic oxycodone: why does the route make a difference? Anesthesiology. 2006;105:801-812. (Pubitemid 44477327)
15. Lemberg K, Kontunen VK, Viljakka K, Kylanlahti I, Yli-Kauhaluoma J, Kalso E. Morphine, oxycodone, methadone and its enantiomers in different models of nociception in the rat. Anesth Analg. 2006;102:1768-1774. (Pubitemid 43799854)
16. Schug SA, Zech D, Grond S. Adverse effects of systemic opioid analgesics. Drug Safety. 1992;7:200-213.
17. Lawlor PG and Bruera E. Side-effects of opioids in chronic pain treatment. Curr OpinAnaesthesiol. 1998;11:539-545. (Pubitemid 28484499)
18. Holzer P. Treatment of opioid-induced gut dysfunction. Expert Opin Invest Drugs 2007;16:181-194. (Pubitemid 46206632)
19. Mansour A, Fox CA, Aki H, Watson SJ. Opioid-receptor mRNA expression in the rat CNS: anatomical and functional implications. Trends Neurosci. 1995;18:22-29.
20. Jordan BA, Devi LA. G-protein-coupled receptor heterodimer-azation modulates receptor function. Nature. 1999;17:697-700. (Pubitemid 29289066)
21. Gomes I, Jordan BA, Gupata A, Trapaidze N, Nagy V, Devi LA. Heterodimerization of mu and delta opioid receptors: a role in opiate synergy. J Neurosci. 2000;15:RC110.
22. Galandrin S, Oligny-Longpre G, Bouvier M. The evasive nature of drug effcacy: implications for drug discovery. Trends Pharmacol Sci. 2007;28:423-430. (Pubitemid 47087968)
23. Pan YX, Xu J, Xu M, Rossi GC, Matulonis JE, Pasternak GW. Involvement of exon 11-associated variants of the mu opioid receptor MOR-1 in heroin, but not morphine, actions. Proc Natl Acad Sci USA. 2009;24:4917-4922.
24. McPherson J, Rivero G, Baptist M, Llorente J, Al-Sabah S, Krasel C, Dewey WL, Bailey CP, Rosethorne EM, Charlton SJ, Henderson G, Kelly E. μ-Opoioid receptors: correlation of agonist effcacy for signaling with ability to activate internalization. Mol Pharmacol. 2010;78:756-766.